Identification and validation of novel pharmaceutical drug targets for cardiovascular disease

Fact Sheet

Project Information

CARTARDIS

Grant agreement ID: 602936

Funded under FP7-HEALTH

Overall budget € 7 980 425

Closed project

EU contribution € 5 973 521

Start date 1 October 2013

End date 30 September 2017

Coordinated by

NEDERLANDSE ORGANISATIE VOOR TOEGEPAST NATUURWETENSCHAPPELIJK ONDERZOEK - TNO

Netherlands

Objective

"Cardiovascular disease (CVD) is one of the major diseases in Europe and the Western world, killing over 2 million people per year in Europe alone and is the foremost cause of premature mortality and disability-adjusted life years, representing an annual economic cost of ~€ 192 billion in direct and indirect healthcare expenses. The available therapies are insufficient to fulfill the need. The introduction of statins has reduced morbidity and mortality of atherosclerosis by 30%, however a large untreated residual cardiovascular risk remains even in cohorts of treated patients. Currently, many targets for CVD treatment have been selected based on mechanism
of action and inference of functions in cellular models to clinical systems, and lack the rigorous clinical validation needed to maximize the chance for successful clinical drug development. Consequently, new drugs that modulate the activity of such targets fail later in clinical development by lack of efficacy or induction of safety liabilities due to off-target effects. To increase the success rate for clinical development of novel therapies in CVD, we will follow an innovative approach by using: 1. Independent and large-scale population studies from which novel targets with strong correlation to clinical phenotypes are deduced; 2. Translational disease-mimicking models (cellular and animal) to validate novel drug targets; 3. High quality human biobanks to confirm the molecular relevance of targets in diseased cardiovascular tissues; 4. A stringent pharmaceutical drug discovery process for prioritization of drugable targets. An important concept, in line with the changed pharmaceutical business model, is that these steps can best be executed by a functional network of clinical academic centers and specialized SMEs under the guidance of established and experienced drug discovery researchers from industry that brings together the right components and expertise to execute such a modular target discovery process."

**Fields of science**

```
> > >
> > >
> > >
> > >
> > >
```

**Programme(s)**

**Topic(s)**

**Call for proposal**

FP7-HEALTH-2013-INNOVATION-1

**Funding Scheme**

**Coordinator**

[NEERLANDSE ORGANISATIE VOOR TOEGEPAST NATUURWETENSCHAPPENLIJK ONDERZOEK - TNO]
HELMHOLTZ ZENTRUM MUNCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH

Germany

EU contribution
€ 700 083

Address
Ingolstaedter Landstrasse 1
85764 Neuherberg

Activity type
Research Organisations

Website
Contact the organisation

Administrative Contact
Juergen Ertel (Dr.)

KAROLINSKA INSTITUTET

Sweden

EU contribution
€ 598 000

Address
Nobels Vag 5
17177 Stockholm

Activity type
Higher or Secondary Education Establishments

Website
Contact the organisation

Administrative Contact
Kindaker Therese (Mrs.)

ASTRAZENECA AB

Sweden

EU contribution
€ 250 112

Address

Activity type
<table>
<thead>
<tr>
<th>Organisation</th>
<th>Type</th>
<th>EU Contribution</th>
<th>Address</th>
<th>Activity Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaestra Maelarhamnen</td>
<td>Private for-profit entities</td>
<td></td>
<td>151 85 Soedertaelje</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(excluding Higher or Secondary Education Establishments)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Website** Contact the organisation

**Administrative Contact** Eva Hurt-Camejo (Prof.)

<table>
<thead>
<tr>
<th>Organisation</th>
<th>Type</th>
<th>EU Contribution</th>
<th>Address</th>
<th>Activity Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>HJARTAVERND SES</td>
<td></td>
<td>€ 499 499</td>
<td>Holtasmari 1 201 Kopavogur</td>
<td>Research Organisations</td>
</tr>
</tbody>
</table>

**Website** Contact the organisation

**Administrative Contact** Vilmundur Gudnason (Prof.)

<table>
<thead>
<tr>
<th>Organisation</th>
<th>Type</th>
<th>EU Contribution</th>
<th>Address</th>
<th>Activity Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACADEMISCH ZIEKENHUIS LEIDEN - LEIDS UNIVERSITAIR MEDISCH CENTRUM</td>
<td>Research Organisations</td>
<td>€ 300 720</td>
<td>Albinusdreef 2 2333 ZA Leiden</td>
<td>Higher or Secondary Education Establishments</td>
</tr>
</tbody>
</table>

**Website** Contact the organisation

**Administrative Contact** Jan Lindeman (Dr.)

<table>
<thead>
<tr>
<th>Organisation</th>
<th>Type</th>
<th>EU Contribution</th>
<th>Address</th>
<th>Activity Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>CARDIOGENX BV</td>
<td></td>
<td>€ 701 024</td>
<td>Lichtenauerlaan 30 3006AG Rotterdam</td>
<td>Private for-profit entities (excluding Higher or Secondary Education)</td>
</tr>
</tbody>
</table>

**Website** Contact the organisation

**Administrative Contact**
POLYGENE AG

Switzerland
EU contribution
€ 697 930

Address
Riedmattstrasse 9
8153 Rümlang

Activity type
Private for-profit entities
(excluding Higher or Secondary Education Establishments)

Website
Contact the organisation

Administrative Contact
Dharminder Chahal (Mr.)

BIONEER A/S

Denmark
EU contribution
€ 296 000

Address
Kogle Alle 2
2970 Hoersholm

Activity type
Research Organisations

Website
Contact the organisation

Administrative Contact
Doron Shmerling (Dr.)

IMABIOTECH SAS

France
EU contribution
€ 296 000

Address
152 Rue Du Docteur Yersin
59120 Loos

Activity type
Private for-profit entities
(excluding Higher or Secondary Education Establishments)

Website
Contact the organisation
<table>
<thead>
<tr>
<th>Organisation</th>
<th>Country</th>
<th>EU Contribution</th>
<th>Address</th>
<th>Activity Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>MORPHISTO EVOLUTIONSFORSCHUNG UND ANWENDUNG GMBH</td>
<td>Germany</td>
<td>€ 295 000</td>
<td>Weismullerstrasse 45 60314 Frankfurt Am Main</td>
<td>Private for-profit entities (excluding Higher or Secondary Education Establishments)</td>
</tr>
<tr>
<td>UMEA UNIVERSITET</td>
<td>Sweden</td>
<td>€ 200 000</td>
<td>Universitetomradet 901 87 Umea</td>
<td>Higher or Secondary Education Establishments</td>
</tr>
<tr>
<td>MAARTEN DANIEL SOLLEWIJN GELPKE</td>
<td>United Kingdom</td>
<td>€ 199 800</td>
<td>Sherbrooke Way 64 KT4 8BP Worcester Park Surrey</td>
<td>Private for-profit entities (excluding Higher or Secondary Education Establishments)</td>
</tr>
</tbody>
</table>